UroGen Pharma Ltd. (NASDAQ: URGN) had its price target lowered by analysts at HC Wainwright from $64.00 to $55.00. They now have a "buy" rating on the stock.
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 [Yahoo! Finance]
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)